Cartesian Therapeutics Goodwill

Cartesian Therapeutics posts a goodwill of $48M as of June 2026. That compares with $48M in the prior-year period — up 0.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Cartesian Therapeutics's goodwill was $48M. The latest reading is $48M — essentially flat versus a year earlier (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Goodwill is one piece of Cartesian Therapeutics's financial statement story. At $48M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RNAC's goodwill usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cartesian Therapeutics's other metric pages and overview cover the third.

Judging Cartesian Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in goodwill easier to interpret. Start with $48M here, then scan peer and history charts to see if the gap is persistent.